Geoffrey Y. Ku, MD, elaborates on the promising PRS-343 compoundPart ofESMO CongressSep 26, 20203 Min WatchUp NextRobert L. Coleman, MD, FACOG, FACS, shares results of the innovaTV 204 study in cervical cancerUp NextDavid S. Hong, MD, regarding the Phase I clinical trial investigating sotorasib (AMG 510)Up NextNicholas James, MD, PhD, offers a summary of the STAMPEDE study to dateDescriptionCopy LinkDr. Ku, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of PRS-343 and why this compound looks promising Show More© 2025 HealthCentral LLC. All rights reserved.Copy LinkESMO CongressBreast CancerAbemaciclib or Ribociclib in Early Breast Cancer?Erin Frances Cobain, MD; Manali Bhave, MD; Stephanie Graff, MDVideoNew data and a recent FDA approval mean that some patients with HR-positive, HER2-negative early-stage breast cancer can choose abemaciclib or ribociclib. Breast CancerAbemaciclib or Ribociclib in Early Breast Cancer?Erin Frances Cobain, MD; Manali Bhave, MD; Stephanie Graff, MDVideoNew data and a recent FDA approval mean that some patients with HR-positive, HER2-negative early-stage breast cancer can choose abemaciclib or ribociclib. Breast CancerStudy “Changes the Conversation” in Breast CancerStephanie Graff, MD; Manali Bhave, MD; Erin Frances Cobain, MDVideoA new finding from the DESTINY-Breast12 trial “changes the conversation” in metastatic breast cancer care. Our panel discusses what this means for practice. Breast CancerStudy “Changes the Conversation” in Breast CancerStephanie Graff, MD; Manali Bhave, MD; Erin Frances Cobain, MDVideoA new finding from the DESTINY-Breast12 trial “changes the conversation” in metastatic breast cancer care. Our panel discusses what this means for practice. Melanoma & Skin CancerTrial Updates for PD-1-Resistant MelanomaAlexander N. Shoushtari, MDVideoAlexander N. Shoushtari, MD, breaks down data from a trio of key studies in PD-1-resistant melanoma that were recently presented at ESMO 2024. Melanoma & Skin CancerTrial Updates for PD-1-Resistant MelanomaAlexander N. Shoushtari, MDVideoAlexander N. Shoushtari, MD, breaks down data from a trio of key studies in PD-1-resistant melanoma that were recently presented at ESMO 2024. Breast CancerExercise Benefits Survival in Breast CancerNeil OsterweilNews3 Min ReadLong-term data show that high-intensity exercise with resistance training in breast cancer survivors reduced the risk for death at 8 years of follow-up. Breast CancerExercise Benefits Survival in Breast CancerNeil OsterweilNews3 Min ReadLong-term data show that high-intensity exercise with resistance training in breast cancer survivors reduced the risk for death at 8 years of follow-up. Breast CancerEarly Breast Cancer Radiotherapy Practice Change?Neil OsterweilNews3 Min ReadPatients with early breast cancer can avoid two extra weeks of radiation to regional lymph nodes, according to data from HYPOG-01 shared at ESMO 2024. Breast CancerEarly Breast Cancer Radiotherapy Practice Change?Neil OsterweilNews3 Min ReadPatients with early breast cancer can avoid two extra weeks of radiation to regional lymph nodes, according to data from HYPOG-01 shared at ESMO 2024. Breast CancerPractice-Changing Data in TNBC From ESMO 2024Neil OsterweilNews4 Min ReadTNBC patients had improved OS with neoadjuvant pembro plus chemo followed by adjuvant pembro, according to practice-changing data shared at ESMO 2024. Breast CancerPractice-Changing Data in TNBC From ESMO 2024Neil OsterweilNews4 Min ReadTNBC patients had improved OS with neoadjuvant pembro plus chemo followed by adjuvant pembro, according to practice-changing data shared at ESMO 2024. Hepatocellular Carcinoma (HCC)New Option for Patients With Liver Cancer?Leah LawrenceNews3 Min ReadLenvatinib and pembrolizumab plus transarterial chemoembolization improved PFS in intermediate-stage HCC, according to data from LEAP-012 shared at ESMO 2024. Hepatocellular Carcinoma (HCC)New Option for Patients With Liver Cancer?Leah LawrenceNews3 Min ReadLenvatinib and pembrolizumab plus transarterial chemoembolization improved PFS in intermediate-stage HCC, according to data from LEAP-012 shared at ESMO 2024. Rare Cancers and DisordersNew Standard of Care for Advanced Anal CancerNeil OsterweilNews4 Min ReadCarboplatin plus paclitaxel and retifanlimab is a new standard of care in advanced and metastatic squamous cell anal carcinoma, said an expert at ESMO 2024. Rare Cancers and DisordersNew Standard of Care for Advanced Anal CancerNeil OsterweilNews4 Min ReadCarboplatin plus paclitaxel and retifanlimab is a new standard of care in advanced and metastatic squamous cell anal carcinoma, said an expert at ESMO 2024. Small Cell Lung Cancer (SCLC)Data From "Astounding" SCLC Trial Raise QuestionNeil OsterweilNews5 Min ReadNew data from the ADRIATIC trial shared at ESMO 2024 show a consistent OS benefit with durvalumab in LS-SCLC across subgroups but also contain a puzzling finding. Small Cell Lung Cancer (SCLC)Data From "Astounding" SCLC Trial Raise QuestionNeil OsterweilNews5 Min ReadNew data from the ADRIATIC trial shared at ESMO 2024 show a consistent OS benefit with durvalumab in LS-SCLC across subgroups but also contain a puzzling finding. Prostate CancerDrug Combo Changes Practice in Prostate CancerLeah LawrenceNews3 Min ReadData from the PEACE-III trial shared at ESMO 2024 showed that enzalutamide plus radium-233 improves survival in metastatic castration-resistant prostate cancer. Prostate CancerDrug Combo Changes Practice in Prostate CancerLeah LawrenceNews3 Min ReadData from the PEACE-III trial shared at ESMO 2024 showed that enzalutamide plus radium-233 improves survival in metastatic castration-resistant prostate cancer. Cervical CancerCheers at ESMO 2024 for Cervical Cancer OS DataNeil OsterweilNews4 Min ReadExperts at ESMO 2024 say pembro plus concurrent chemoradiotherapy should now be the standard of care for untreated, high-risk locally advanced cervical cancer. Cervical CancerCheers at ESMO 2024 for Cervical Cancer OS DataNeil OsterweilNews4 Min ReadExperts at ESMO 2024 say pembro plus concurrent chemoradiotherapy should now be the standard of care for untreated, high-risk locally advanced cervical cancer. Bladder CancerData “Immediately” Change Practice in Bladder CancerLeah LawrenceNews3 Min ReadData at ESMO 2024 show perioperative durvalumab plus chemo boosts survival in muscle-invasive bladder cancer, prompting a call for an immediate practice change. Bladder CancerData “Immediately” Change Practice in Bladder CancerLeah LawrenceNews3 Min ReadData at ESMO 2024 show perioperative durvalumab plus chemo boosts survival in muscle-invasive bladder cancer, prompting a call for an immediate practice change.
